TransMedics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average and near the bottom of the universe on momentum.
- Signal has read STRONG SELL for 3 days.
- Its last 4 Sell calls were followed by roughly flat moves (-1%) three months out.
- Recent price momentum is -18.7% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 25.6% of float.
- Analyst tilt is Buy.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation D+
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 23.2x | Better than 33% |
| Forward P/E | 32.5x | Better than 15% |
| Price / Sales | 4.4x | Better than 26% |
| P/E vs own 5-yr range | 67th pctl | Better than 41% |
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability A
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 59.9% | Better than 74% |
| Operating margin | 17.9% | Better than 72% |
| Net margin | 31.4% | Better than 91% |
| Return on equity | 54.2% | Better than 95% |
| Return on invested capital | 23.1% | Better than 93% |
Momentum C+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -10.0% | Better than 51% |
| 6-month return | 23.7% | Better than 86% |
| 12-month return (ex latest month) | -46.0% | Better than 4% |
| Distance below 52-week high | 45.4% | Better than 23% |
Financial Health B-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 7.1x | Better than 91% |
| Debt to assets | 48.6% | Better than 17% |
| Interest coverage | 8.8x | Better than 70% |
| Free cash flow / net income | 70.2% | Better than 21% |
Analyst View B-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 77.8% | Better than 57% |
| Upside to average target | 22.9% | Better than 38% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 94.02
- Open
- 90.81
- Day range
- 83.89 - 91.62
- Avg price
- 86.44
- Volume
- 1.59M
- Turnover
- 137.27M
- Turnover ratei
- 4.72%
- Volume ratioi
- 1.79
- Amplitudei
- 8.22%
- 52-week rangei
- 60.11 - 156.00
Valuation
- P/Ei
- 17.51
- P/E (TTM)i
- 23.23
- P/Bi
- 5.38
- EPSi
- 4.87
- Book value / shi
- 15.86
- Net profit
- 169.15M
- Net assets
- 550.71M
Share structure
- Market cap
- 2.96B
- Float capi
- 2.87B
- Shares out
- 34.73M
- Float sharesi
- 33.62M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2019-05-02
45.4% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-5.83M net over the window
Short interest
- Shares short
- 8.88M
- % of floati
- 25.60%
- Days to coveri
- 10.22
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of TransMedics (TMDX)?
TransMedics last traded at 85.25. This page shows a periodic quote snapshot. Check the displayed quote time.
What is TransMedics's market cap?
About 2.96B.
What is the P/E ratio of TransMedics?
The trailing twelve-month P/E is 23.23, below its own 5-year average of 159.86 — toward the top of its historical range (67.30% percentile). See the Valuation tab for the full history.
Does TransMedics pay a dividend?
TransMedics does not currently pay a regular dividend.
Is TransMedics a buy according to analysts?
The consensus of 9 analysts is a Buy rating, with an average 12-month price target of 104.75, which implies 22.9% upside from the current price. This is not investment advice.
What is TransMedics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates TransMedics a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.
Quote time 2026-11-20 20:02:23 · For reference only, not investment advice and not tailored to your situation.
TransMedics discussion 0 comments